<DOC>
	<DOCNO>NCT01674985</DOCNO>
	<brief_summary>The purpose study investigate whether infusion G-CSF mobilize HLA-mismatched peripheral blood stem cell ( G-PBSC ) combine decitabine cytarabine chemotherapy improve outcome myelodysplastic syndrome ( MDS ) patient .</brief_summary>
	<brief_title>Microtransplantation With Decitabine Cytarabine Improves Patient Outcomes Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<criteria>patient 10 90 year old primary treatmentrelated MDS chronic myelomonocytic leukemia ; International Prognostic Scoring System ( IPSS ) intermediate1 , intermediate2 , high risk ; bone marrow blast &gt; 11 % &lt; = 10 % poor cytogenetics ; lack HLAidentical donor ; Eastern Cooperative Oncology Group ( ECOG ) performance status 02 ; adequate cardiac hepatorenal function . HLAidentical donor</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Decitabine</keyword>
	<keyword>microtransplantation</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>chemotherapy</keyword>
</DOC>